Trial Profile
A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma Who Have Received Prior Systemic Anticancer Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Pharma
- 05 Jan 2023 Final results of cumulative data to final database lock published in the Hepatology Research
- 25 Aug 2021 Status changed from active, no longer recruiting to completed.
- 06 May 2021 Planned End Date changed from 31 Mar 2021 to 30 Jun 2021.